The primary dose-limiting toxicity of stereotactic radiosurgery (SRS) is radiation necrosis (RN), which occurs after approximately 5%to10%0% of treatments.
Karl Hostetler, MD, then at the University of California at San Diego, had originally designed the drug to avoid the primary dose-limiting toxicity of cidofovir, kidney damage.
However, the primary dose-limiting toxicity of topotecan is myelosuppression, restricting its use at high doses.
However, in 3-week CAPIRI, diarrhoea, and not neutropenia, may be the primary dose-limiting toxicity (Carlini et al, 2005; Koopman et al, 2006).
Not surprisingly, patients experience a wide range of toxicities and severities, with the primary dose-limiting complications being neutropenia, leukopenia, mucositis and diarrhoea (Tsalic et al, 2003; Patel et al, 2004).
The primary endpoints were safety, tolerability and level at which dose limiting toxicity occurred.
Neutropenia is also the primary dose-limiting cause for delays and reductions in relative dose-intensity, potentially compromising patient outcomes, including overall survival and complete response rates [ 15– 17].
In particular, PPE, which is the primary dose-limiting side effect of PLD, occurred in a lower percentage of cases with respect to what was reported by the main trials testing PLD (Gordon et al, 2000, 2001; Safra et al, 2001), requiring the discontinuation of treatment in only 2.8% of cases.
Surgical resection is the primary treatment standard, though complete resection is nearly impossible due to close proximity to critical and hence also dose limiting organs for radiation therapy.
IRs were dose limiting above 250mg.
